Pathogenesis, pathophysiology, and classification

Clinical Reviews in Bone and Mineral Metabolism

Volumn 2, Issue 3, 2004, Pages 187-207

  Kleinman, Jack G ^a,b   Wesson, Jeffrey A ^a   Sudakoff, Gary S ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Calcium oxalate; Calcium phosphates; Cystine; Nephrolithiasis; Struvite; Uric acid; Urine macromolecules; Urolithiasis

Indexed keywords

ACETAZOLAMIDE; ALLOPURINOL; ANTIBIOTIC AGENT; BACTERIAL ENZYME; CALCIUM OXALATE; CALCIUM PHOSPHATE; CYSTINE; DRUG METABOLITE; EPHEDRINE; FELBAMATE; FUROSEMIDE; GUAIFENESIN; INDINAVIR; OMEGA 3 FATTY ACID; OSTEOPONTIN; PROTHROMBIN; STRUVITE; SULFONAMIDE; TAMM HORSFALL GLYCOPROTEIN; TRIAMTERENE; UREASE; URIC ACID; VITAMIN K GROUP; WARFARIN;

ABNORMAL URINE COMPOSITION; CRYSTALLIZATION; CRYSTALLURIA; CYSTINURIA; DISEASE CLASSIFICATION; DRUG EXCRETION; HUMAN; HYPERCALCIURIA; HYPEROXALURIA; HYPERURICOSURIA; HYPOCITRATURIA; KIDNEY CALCIFICATION; MACROMOLECULE; NEPHROLITHIASIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHOSPHATURIA; REVIEW; STONE FORMATION; URIC ACID STONE; URINE PH; URINE VOLUME;

EID: 26244453903     PISSN: 15348644     EISSN: None     Source Type: Journal    
DOI: 10.1385/BMM:2:3:187     Document Type: Review

References (138)

1. Coe FL, Parks JH, Asplin JR 1992 The pathogenesis and treatment of kidney stones. N Engl J Med 327:1141-1152.
2. Lemann J Jr, Pleuss JA, Worcester EM, Hornick L, Schrab D, Hoffmann RG. 1996 Urinary oxalate excretion increases with body size and decreases with increasing dietary calcium intake among healthy adults. Kidney Int 49:200-208.
3. Lieske JC, Walsh-Reitz MM, Toback FG. 1992 Calcium oxalate monohydrate crystals are endocytosed by renal epithelial cells and induce proliferation. Am J Physiol (Renal Fluid Electrolyte Physiol) 262/31:F622-F630.
4. Wiessner JH, Kleinman JG, Blumenthal SS, Garancis JC, Mandel GS. 1987 Calcium oxalate crystal interaction with rat renal inner papillary collecting tubule cells. J Urol 138:640-643.
5. Verkoelen CF, Romijn JC, de Bruijn WC, Boeve ER, Cao LC, Schroder FH. 1993 Oxalate handling and interaction with calcium oxalate crystals by renal epithelial cells cultured on porous supports. J Urol 149:439A.
6. Mandel NS, Mandel GS. 1989 Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition. J Urol 142:1516-1521.
7. Mandel N, Mandel G. 1996 Urinary tract stone incidence in the U.S. veteran population: a 12 year compositional survey. In: Urolithiasis 1996. Pak CY, Resnick MI, Preminger GM. eds. Millet the Printer, Dallas TX, 454-455.
8. Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. 1996 Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: A 5-year randomized prospective study. J Urol 155:839-843.
9. Harvey JA, Hill KD, Pak CY. 1990 Similarity of urinary risk factors among stone-forming patients in five regions of the United States. J Lithotr Stone Dis 2:124-132.
10. Levy FL, Adams-Huet B, Pak CY. 1995 Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 98:50-59.
11. Worcester EM. 2002 Stones from bowel disease. Endocrinol Metab Clin North Am 31:979-999.
12. Zerwekh JE, Reed-Gitomer BY, Pak CY. 2002 Pathogenesis of hypercalciuric nephrolithiasis. Endocrinol Metab Clin North Am. 31:869-884.
13. Coe FL, Parks JH, Moore ES. 1979. Familial idiopathic hypercalciuria. N Engl J Med 300:337-340.
14. Pak CY, McGuire J, Peterson R, Britton F, Harrod MJ. 1981. Familial absorptive hypercalciuria in a large kindred. J Urol 126:717-719.
15. Li X-Q, Tembe V, Horwitz GM, Bushinsky DA, Favus MJ. 1993 Increased intestinal vitamin D receptor in genetic hypercalciuric rats. A cause of intestinal calcium hyperabsorption. J Clin Invest 91:661-667.
16. Zerwekh JE, Hughes MR, Reed BY, et al. 1995 Evidence for normal vitamin D receptor messenger ribonucleic acid and genotype in adsorptive hypercalciuria. J Clin Endocrinol Metab 80:2960-2965.
17. Reed BY, Heller HJ, Gitomer WL, Pak CY. 1999 Mapping a gene defect in absorptive hypercalciuria to chromosome 1q23.3- q24. J Clin Endocrinol Metab 84:3907-3913.
18. Baggio B, Gambaro G. 1999 Abnormal arachidonic acid content of membrane phospholipids - the unifying hypothesis for the genesis of hypercalciuria and hyperoxaluria in idiopathic calcium nephrolithiasis. Nephrol Dial Transplant 14:553-555.
19. Buck AC, Davies RL, Harrison T. 1991 The protective role of eicosapentaenoic acid [EPA] in the pathogenesis of nephrolithiasis. J Urol 146:188-194.
20. Baggio B, Budakovic A, Nassuato MA, et al. 2000 Plasma phospholipid arachidonic acid content and calcium metabolism in idiopathic calcium nephrolithiasis. Kidney Int 58:1278-1284.
21. Scheinman SJ, Cox JP, Lloyd SE, et al. 2000 Isolated hypercalciuria with mutation in CLCN5: relevance to idiopathic hypercalciuria. Kidney Int 57:232-239.
22. Thakker RV 2000 Pathogenesis of Dent's disease and related syndromes of X-linked nephrolithiasis. Kidney Int 57:787-793.
23. Silva IV, Cebotaru V, Wang H, et al. 2003 The ClC-5 knockout mouse model of Dent's disease has renal hypercalciuria and increased bone turnover. J Bone Miner Res 18:615-623.
24. Reinhart SC, Norden AG, Lapsley M, et al. 1995 Characterization of carrier females and affected males with X-linked recessive nephrolithiasis. J Am Soc Nephrol 5:1451-1461.
25. Danpure CJ, Rumsby G. 2004 Molecular aetiology of primary hyperoxaluria and its implications for clinical management. Expert Rev Mol Med 2004:1-16.
26. Sidhu H, Hoppe B, Hesse A, et al. 1998 Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. The Lancet 352:1026-1029.
27. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. 1993 A prospective study of dietary calcum and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 328:833-838.
28. Borghi L, Schianchi T, Meschi T. et al. 2002 Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 346:77-84.
29. Aruga S, Wehrli S, Kaissling B, et al. 2000 Chronic metabolic acidosis increases NaDC-1 mRNA and protein abundance in rat kidney. Kidney Int 58:206-215.
30. Sakhaee K, Nigam S, Snell P, Hsu MC, Pak CY. 1987. Assessment of the pathogenetic role of physical exercise in renal stone formation. J Clin Endocrinol Metab 65:974-979.
31. Borghi E, Meschi T, Amato F, Novarini A, Romanelli A, Cigala F. 1993 Hot occupation and nephrolithiasis. J Urol 150:1757-1760.
32. Robertson W.G. 2003 Renal stones in the tropics. Semin Nephrol 23:77-87.
33. Ombra MN, Forabosco P, Casula S, et al. 2001. Identification of a new candidate locus for uric acid nephrolithiasis. Am J Hum Genet 68:1119-1129.
34. Shekarriz B, Stoller ME. 2002 Uric acid nephrolithiasis: current concepts and controversies. J Urol 168:1307-1314.
35. Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. 2003 The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int 64:1022-1026.
36. Wortmann RE, Kelly WJ. 2001. Gout and Hyperuricemia. In: Kelly's Textbook of Rheumatology. S. Ruddy, Harris ED Jr, Sledge CB, Budd RC, Sergent JS, eds. W.B. Saunders, Philadelphia. 1339-1376.
37. Yu T,. Gutman AB. 1967. Uric acid nephrolithiasis in gout. Predisposing factors. Ann Intern Med 67:1133-1148.
38. Pak CY, Poindexter JR, Peterson RD, Koska J, Sakhaee K. 2002 Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis. Urology 60:789-794.
39. Sakhaee K, Adams-Huet B, Moe OW, Pak CY. 2002 Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int 62:971-979.
40. Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K. 2004 The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 65:386-392.
41. Moe OW, Abate N, Sakhaee K. 2002 Pathophysiology of uric acid nephrolithiasis. Endocrinol Metab Clin North Am 31:895-914.
42. Kaufman JM, Greene ME, Seegmiller JE. 1968. Urine uric acid to creatinine ratio - a screening test for inherited disorders of purine metabolism. Phosphoribosyltransferase (PRT) deficiency in X-linked cerebral palsy and in a variant of gout. J Pediatr 73:583-592.
43. Sperling O, Eilam G, Sara PB, De Vries A. 1972. Accelerated erythrocyte 5-phosphoribosyl-1-pyrophosphate synthesis. A familial abnormality associated with excessive uric acid production and gout. Biochem Med 6:310-316.
44. Iida S, Matsuoka K, Inoue M, Tomiyasu K, Noda S. 2003 Calcium nephrolithiasis and distal tubular acidosis in type 1 glycogen storage disease. Int J Urol 10:56-58.
45. Howell RR, Ashton DM, Wyngaarden JB. 1962. Glucose-6-phosphatase deficiency glycogen storage disease. Studies on the interrelationships of carbohydrate, lipid, and purine abnormalities. Pediatrics 29:553-565.
46. Ogawa A, Watanabe K, Minejima N. 1985. Renal xanthine stone in Lesch-Nyhan syndrome treated with allopurinol. Urology 26:56-58.
47. Gok F, Ichida K, Topaloglu R. 2003 Mutational analysis of the xanthine dehydrogenase gene in a Turkish family with autosomal recessive classical xanthinuria. Nephrol Dial Transplant 18:2278-2283.
48. Tisler A, Pierratos A, Honey J.D, Bull SB, Rosivall L, Logan AG. 2002 High urinary excretion of uric acid combined with high excretion of calcium links kidney stone disease to familial hypertension. Nephrol Dial Transplant 17:253-259.
49. Grover PK, Ryall RL. 1994 Urate and calcium oxalate stones: from repute to rhetoric to reality. Miner Electrolyte Metab 20:361-370.
50. Pak CY, Poindexter JR, Peterson RD, Heller HJ. 2004 Biochemical and physicochemical presentations of patients with brushite stones. J Urol 171:1046-1049.
51. Whitson PA, Pietrzyk RA, Morukov BV, Sams CR 2001. The risk of renal stone formation during and after long duration space flight. Nephron 89:264-270.
52. Yagisawa T, Kobayashi C, Hayashi T, Yoshida A, Toma H. 2001. Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney. Am J Kidney Dis 37:1140-1143.
53. Asplin JR, Parks JH, Coe FL. 1997 Dependence of upper limit of metastability on supersaturation in nephrolithiasis. Kidney Int 52:1602-1608.
54. Asplin JR, Mandel NS, Coe FL. 1996 Evidence of calcium phosphate supersaturation in the loop of Henle. Am J Physiol 270:F604-F613.
55. Evan AP, Lingeman JE, Coe FL, et al. 2003 Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 111:607-616.
56. Cotran RS, Kumar V, Collins T. 1999 The Kidney. In: Robbins Pathologic Basis of Disease. W. B. Saunders, Philadelphia. 930-996.
57. Dyer RB, Chen MY, Zagoria RJ. 1998 Abnormal calcifications in the urinary tract. Radiographics 18:1405-1424.
58. Hildebrandt F, Jungers P, Grunfeld J. 2001. Nephronophthisis, Medullary Cystic and Medullary Sponge Kidney Disease. In: Diseases of the Kidney and Urinary Tract. RW Schrier, ed. Lippincott Williams & Wilkins, Philadelphia, 521-546.
59. Sayer JA, Pearce SH. 2001. Diagnosis and clinical biochemistry of inherited tubulopathies. Ann Clin Biochem 38:459-470.
60. Benigno V, Canonica CS, Bettinelli A, von Vigier RO, Truttmann A.C, Bianchetti M.G. 2000 Hypomagnesaemia-hypercalciuria-nephrocalcinosis: a report of nine cases and a review. Nephrol Dial Transplant 15:605-610.
61. Ismail EA, Abul SS, Sabry MA. 1997 Nephrocalcinosis and urolithiasis in carbonic anhydrase II deficiency syndrome. Eur J Pediatr 156:957-962.
62. Cohen TD, Preminger G.M. 1996 Struvite calculi. Semin Nephrol 16:425-434.
63. Griffith DP, Musher DM, Itin C. 1976. Urease. The primary cause of infection-induced urinary stones. Invest Urol 13:346-350.
64. Elliot JS, Sharp RF, Lewis L. 1959. The solubility of struvite in urine. J Urol 81:366-368.
65. Nickel JC, Emtage J, Costerton JW. 1985. Ultrastructural microbial ecology of infection-induced urinary stones. J Urol 133:622-627.
66. Bisceglia L, Purroy J, Vidal-Jimenez M, et al. 2001. Cystinuria type I: Identification of eight new mutations in SLC3A1. Kidney Int 59:1250-1256.
67. Shekarriz B, Stoller M.L. 2002 Cystinuria and other non-calcareous calculi. Endocrinol Metab Clin North Am 31:951-977.
68. Dent CE, Senior B. 1955. Studies on the treatment of cystinuria. Br J Urol 27:317-332.
69. Crawhall JC, Purkiss P, Watts RW, Young EP. 1969. The excretion of amino acids by cystinuric patients and their relatives. Ann Hum Genet 33:149-169.
70. Font MA, Feliubadalo L, Estivill X, et al. 2001. Functional analysis of mutations in SLC7A9, genotype-phenotype correlation in non-Type I cystinuria. Hum Mol Genet 10:305-316.
71. Saito M, Takahashi C, Ishida G, Kadowaki H, Hirakawa S, Miyagawa I. 2001. Acute renal failure associated with sulfur calculi. J Urol 165:1985-1986.
72. Sasson JP, Dratch PL, Shortsleeve MJ. 1992. Renal US findings in sulfadiazine-induced crystalluria. Radiology 185:739-740.
73. Stote RM, Smith LH, Dubb JW, Moyer TP, Alexander F, Roth JL. 1980. Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy. Ann Intern Med 92:384-385.
74. Assimos DG, Langenstroer P, Leinbach RF, Mandel NS, Stern JM, Holmes RP. 1999 Guaifenesin- and ephedrine-induced stones. J EndoUrol 13:665-667.
75. Powell T, Hsu FF, Turk J, Hruska K. 1998 Ma-huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis 32:153-159.
76. Carey RA, Beg MM, McNally CF, Tannenbaum P. 1984. Triamterene and renal lithiasis: a review. Clin Ther 6:302-309.
77. Sparagana SP, Strand WR, Adams RC. 2001. Felbamate urolithiasis. Epilepsia 42:682-685.
78. Kohan AD, Armenakas NA, Fracchia JA. 1999 Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. J Urol 161:1765-1768.
79. Tiselius HG. 1996 Solution chemistry of supersaturation. In: Kidney Stones, Medical and Surgical Management. Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM, eds. Lippincott-Raven, Philadelphia. 33-64.
80. Robertson WG, Peacock M, Nordin BEC. 1969 Calcium crystalluria in recurrent renal stone formers. Lancet 21-24.
81. Ashby R, Gyory AZ. 1997 A thermodynamic equilibrium model for calcium salt urolithiasis: clinical application. Exp Nephrol 5:246-252.
82. Ashby RA, Byrne JP, Gyory AZ. 1999 Urine is a saturated equilibrium and not a metastable supersaturated solution: evidence from crystalluria and the general composition of calcium salt and uric acid calculi. Urol Res 27:297-305.
83. Schwartz BF, Stoller M.L. 2000 The vesical calculus. Urol Clin North Am 27:333-346.
84. Hemal AK, Sharma SK. 1991. Male urethral calculi. Urol Int 46:334-337.
85. Yuasa T, Kageyama S, Yoshiki T, Okada Y. 2001. Preputial calculi: a case report. Hinyokika Kiyo 47:513-515.
86. Kamai T, Toma T, Kano H, Ishiwata D. 1999 Urethral obstruction due to protruding prostatic calculi. J Urol 162:163-164.
87. Sutor DJ, Wooley SE. 1974 The crystalline composition of prostatic calculi. Br J Urol 46:533-535.
88. de Bruijn WC, Boeve ER, van Run PRWA, et al. 1995 Etiology of calcium oxalate nephrolithiasis in rats. II. The role of the papilla in stone formation. Scanning Microsc 9:115-125.
89. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. 2001. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107:1055-1061.
90. Behrend EI, Chambers AF, Wilson SM, Denhardt DT. 1993 Comparative analysis of two alternative first exons reported for the mouse osteopontin gene. J Biol Chem 268:11172-11175.
91. Young MF, Kerr JM, Termine JD, et al. 1990 cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 7:491-502.
92. Yamate T, Tsuji H, Amasaki N, Iguchi M, Kurita T, Kohri K. 2000 Analysis of osteopontin DNA in patients with urolithiasis. Urological Research 28:159-166.
93. Worcester EM, Blumenthal SS, Beshensky AM, Lewand DL. 1992 The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res 7:1029-1036.
94. Worcester EM, Beshensky AM. 1995 Osteopontin inhibits nucleation of calcium oxalate crystals. Ann NY Acad Sci 760:375-377.
95. Wesson JA, Worcester EM, Wiessner JH, Mandel NS, Kleinman JG. 1998 Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int 53:952-957.
96. Prince CW 1989. Secondary structure predictions for rat osteopontin. Connect Tissue Res 21:15-20.
97. Denhardt DT, Guo X. 1993 Osteopontin: a protein with diverse functions. FASEB J 7:1475-1482.
98. Nagata T, Todescan R, Goldberg HA, Zhang Q, Sodek J. 1989. Sulphation of secreted phosphoprotein I (SPPI, osteopontin) is associated with mineralized tissue formation. Biochem Biophys Res Comm 165:234-240.
99. Butler WT. 1989. The nature and significance of osteopontin. Connect Tissue Res 23:123-136.
100. Hoyer JR, Asplin JR, Otvos L Jr. 2001 Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int 60:77-82.
101. Worcester EM, Kleinman JG, Beshensky AM. 1995 Osteopontin production by cultured kidney cells. Ann NY Acad Sci 760:266-278.
102. Asplin J, Deganello S, Nakagawa YN, Coe FL. 1991 Evidence that nephrocalcin and urine inhibit nucleation of calcium oxalate monohydrate crystals. Am J Physiol 261:F824-F830.
103. Worcester EM, Nakagawa Y, Wabner CE, Coe FL. 1988. Crystal adsorption and growth slowing by nephrocalcin, albumin, and Tamm-Horsfall protein. Am J Physiol 255:F1197-F1205.
104. Hess B, Nakagawa Y, Coe FL. 1989. Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 257:F99-106.
105. Hess B, Nakagawa Y, Parks JH, Coe FL. 1991 Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 260:F569-F578.
106. Marengo SR, Chen DH, Kaung HL, Resnick MI, Yang L. 2002 Decreased renal expression of the putative calcium oxalate inhibitor Tamm-Horsfall protein in the ethylene glycol rat model of calcium oxalate urolithiasis. J Urol 167:2192-2197.
107. Lieske JC, Leonard R, Toback FG. 1995 Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibitied by specific anions. Am J Physiol (Renal Fluid Electrolyte Physiol) 268/37:F604-F612.
108. van Rooijen JJ, Voskamp AF, Kamerling JP, Vliegenthart JF. 1999 Glycosylation sites and site-specific glycosylation in human Tamm-Horsfall glycoprotein. Glycobiology 9:21-30.
109. Kone BC, Schwobel J, Turner P, Mohaupt MG, Cangro CB. 1995 Role of NF-kappa B in the regulation of inducible nitric oxide synthase in an MTAL cell line. Am J Physiol 269:F718-F729.
110. Ryall RL, Grover PK, Stapleton AM, Barrell DK, Tang Y, Simpson RJ. 1995 The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Clin Sci 89:533-541.
111. Grover PK, Ryall RL. 1999 Inhibition of calcium oxalate crystal growth and aggregation by prothrombin and its fragments in vitro: relationship between protein structure and inhibitory activity. Eur J Biochem 263:50-56.
112. Grover PK, Ryall R.L. 2002 Effect of prothrombin and its activation fragments on calcium oxalate crystal growth and aggregation in undiluted human urine in vitro: relationship between protein structure and inhibitory activity. Clin Sci (Lond) 102:425-434.
113. Worcester EM, Sebastian JL, Hiatt JG, Beshensky AM, Sadowski JA. 1993 The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin. Calcif Tissue Int 53:242-248.
114. Buchholz NP, Kim DS, Grover PK, Dawson CJ, Ryall RL. 1999 The effect of warfarin therapy on the charge properties of urinary prothrombin fragment 1 and crystallization of calcium oxalate in undiluted human urine. J Bone Miner Res 14:1003-1012.
115. Grover PK, Dogra SC, Davidson BP, Stapleton AM, Ryall RL. 2000 The prothrombin gene is expressed in the rat kidney: Implications for urolithiasis research. Eur J Biochem 267:61-67.
116. Howe AM, Webster WS. 2000 Warfarin exposure and calcification of the arterial system in the rat. Int J Exp Pathol 81:51-56.
117. Sorensen S, Hansen K, Bak S, Justesen SJ. 1990 An unidentified macromolecular inhibitory constituent of calcium oxalate crystal growth in human urine. Urol Res 18:373-379.
118. Atmani F, Lacour P, Jungers P, Drueke T, Daudon M. 1994 Reduced inhibitory activity of uronic-acid-rich protein in urine of stone formers. Urol Res 22:257-260.
119. Janssen U, Thomas G, Glant T, Phillips A. 2001 Expression of inter-α-trypsin inhibitor and tumor necrosis factor-stimulated gene 6 in renal proximal tubular epithelial cells. Kidney Int 60:126-136.
120. Dawson CJ, Grover PK, Kanellos J, Pham H, Kupczyk G, Oates A, Ryall RL. 1998 Inter-α-inhibitor in calcium stones. Clin Sci (Lond) 95:187-193.
121. Tang Y, Grover PK, Moritz RL, Simpson RJ, Ryall RL. 1995 Is nephrocalcin related to the urinary derivative (bikunin) of inter-α-trypsin inhibitor? Br J Urol 76:425-430.
122. Nakagawa Y, Abram V, Kezdy FJ, Kaiser ET, Coe FL. 1983. Purification and characterization of the principal inhibitor of calcium oxalate monohydrate crystal growth in human urine. J Biol Chem 258 (20):12594-12600.
123. Kobayashi H, Shibata K, Fujie M, Sugino D, Terao T. 1998 Identification of structural domains in inter-α-trypsin involved in calcium oxalate crystallization. Kidney Int 53:1727-1735.
124. Ebisuno S, Nishihata M, Inagaki T, Umehara M, Kohjimoto Y. 1999 Bikunin prevents adhesion of calcium oxalate crystal to renal tubular cells in human urine. J Am Soc Nephrol 10 Suppl 14:S436-S440.
125. Moritama MT, Glenton PA, Khan SR. 2001 Expression of inter-α- inhibitor related proteins in kidneys and urine of hyperoxaluric rats. J Urol 165:1687-1692.
126. Xu Y, Carr PD, Guss JM, Ollis DL. 1998 The crystal structure of bikunin from the inter-α-inhibitor complex: a serine protease inhibitor with two Kunitz domains. J Mol Biol 276:955-966.
127. Wesson JA, Worcester EM, Kleinman JG. 2000 Role of anionic proteins in kidney stone formation: Interaction between model anionic polypeptides and calcium oxalate crystals. J Urol 163:1343-1348.
128. Finlayson B, Reid F. 1978. The expectation of free and fixed particles in urinary stone disease. Invest Urol 15:442-448.
129. Gill WB, Ruggiero K, Straus FH. 1979. Crystallization studies in a urothelial-lined living test tube (the catheterized female rat bladder). I. Calcium oxalate crystal adhesion to the chemically injured rat bladder. Invest Urol 17:257-261.
130. Verkoelen CF, Romijn JC, Cao LC, Boeve ER, de Bruijn WC, Schroder FH. 1996 Crystal-cell interaction inhibition by polysaccharides. J Urol 155:749-752.
131. Yamate T, Kohri K, Umekawa T, Amasaki N, Isikawa Y, Kurita T. 1996 The effect of osteopontin on the adhesion of calcium oxalate crystals to Madin-Darby canine kidney cells. Eur Urol 30:388-393.
132. Bigelow MW, Wiessner JH, Kleinman JG, Mandel NS. 1997 Surface exposure of phosphatidylserine increases calcium oxalate crystal attachment to IMCD cells. Am J Physiol (Renal Fluid Electrolyte Physiol ) 272:F55-F62.
133. Wiessner JH, Hasegawa AT, Hung LY, Mandel NS. 1999 Oxalate-induced exposure of phosphatidylserine on the surface of renal epithelial cells in culture. J Am Soc Nephrol 10 Suppl 14:S441-S445.
134. Verkoelen CF, van der Boom BG, Romijn JC. 2000 Identification of hyaluronan as a crystal-binding mocecule at the surface of migrating and proliferating MDCK cells. Kidney Int 58:1045-1054.
135. Kumar V, Farell G, Deganello S, Lieske JC. 2003 Annexin II is present on renal epithelial cells and binds calcium oxalate monohydrate crystals. J Amer Soc Neph 14:289-297 (Abstr.)
136. Sorokina EA, Wesson JA, Kleinman JG. 2004 An acidic peptide sequence of nucleolin-related protein can mediate the attachment of calcium oxalate to renal tubule cells. J Am Soc Nephrol 15:2057-2065
137. Bigelow MW. Mechanisms of stone crystal attachment to inner medullary collecting duct cells. 0, 1-122. 1996 Medical College of Wisconsin.
138. Wesson JA, Johnson RJMM, Beshensky AM, et al. 2003 Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 14:139-147.